TW EN

scroll

Go Top

高雄醫學大學附設中和紀念醫院-臨床試驗中心KMUH Clinical Trial Center

  • Total Beds1,720
  • Total Doctors834
  • AddressNo.100, Tzyou 1st Rd.,Sanmin,Kaohsiung City 807
  • Emailctc@ms.kmuh.org.tw
  • Phone Number07-3121101 分機 6643、6644

1. Full accredited from the AAHRPP (2018.12, 2022.03) and JCI (2023.03).

2. The first hospital to establish a spinal muscular atrophy treatment team in Taiwan.

3. First site that had been approved by MOHW for face transplant clinical trial in Taiwan.

Site Introduction

Beside taking good care of our patients, Kaohsiung medical university hospital gas devoted every effort in facilitating the competency of clinical trial keeping that clinical trial is the cornerstone in promoting the standard of care and keeping with global medical proficiency. We have signed memorandum of understanding with many international pharmaceutical companies, Metal Industries Research & Development Center (MIRDC), Lu-Ju scientific park. Kaohsiung medical university hospital has become one of major clinical trial center in Taiwan. To consolidate the platform of clinical trial, KMUH enroll center for evidence-base medicine and statistics, and department of laboratory medicine as team member to provide the support from basic science and statistics analysis.

Clinicl Trial Expertise

Hepatitis, Colorectal Cancer, Breast Cancer, Lung Cancer, Spinal Muscular Atrophy

International Accreditation

Full accredited from the AAHRPP in Dec, 2018 and , Mar 2022
3th accredited by Joint Commission International (JCI) in Mar, 2023

GCP Inspection/audit

In 2010/5 and 2016/7, the clinical trial team of Prof. Wan-Long Chuang was approved by US FDA
2015/5, Protocol # HGS1008-C1067, Alfa-2b(alb-IFN)
2016/7, Protocol # GS-US-320-0108, TAF, GS-7340/Viread®

What types of clinical trial do you conduct?

Spotlights

CTC

3th accredited by Joint Commission International (JCI) in Mar, 2023

 

The first hospital to establish a spinal muscular atrophy treatment team in Taiwan.

Publications

CTC

1

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., ... & Zhang, Y. (2023). Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. The Lancet, 401(10370), 49-59.

2

Estephan, L., Lin, Y. C., Lin, Y. T., Chen, Y. H., Pan, S. C., Hsieh, S. M., ... & Lien, C. E. (2023). Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial. Vaccine, 41(23), 3497-3505.

3

Zhou, C., Tang, K. J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., ... & Girard, N. (2023). Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. New England Journal of Medicine, 389(22), 2039-2051.

4

Tsai, H. L., Lin, C. C., Sung, Y. C., Chen, S. H., Chen, L. T., Jiang, J. K., & Wang, J. Y. (2023). The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study. British Journal of Cancer, 129(6), 947-955.

5

Huang, C. W., Hu, H. M., Hsu, W. H., Chen, C. Y., Huang, M. Y., Chen, C. P., ... & Wang, J. Y. (2023). A phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer. Nanomedicine, 18(6), 511-524.

6

Tsai, H. L., Shi, H. Y., Chen, Y. C., Huang, C. W., Su, W. C., Chang, T. K., ... & Wang, J. Y. (2023). Clinical and cost-effectiveness analysis of mFOLOFX6 with or without a targeted drug among patients with metastatic colorectal cancer: inverse probability of treatment weighting. American Journal of Cancer Research, 13(9), 4039.

7

Tsai, H. L., Shi, H. Y., Chen, Y. C., Huang, C. W., Su, W. C., Chang, T. K., ... & Wang, J. Y. (2023). Clinical and cost-effectiveness analysis of mFOLOFX6 with or without a targeted drug among patients with metastatic colorectal cancer: inverse probability of treatment weighting. American Journal of Cancer Research, 13(9), 4039.

8

Chiang, N. J., & Chen, L. T. (2023). Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning. The Lancet, 401(10372), 170-171.

9

Hsieh, C. C., Su, Y. C., Jiang, K. Y., Ito, T., Li, T. W., Kaku-Ito, Y., ... & Shen, C. H. (2023). TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIδ/AKT pathway. Journal of Advanced Research, 43, 45-57.

10

Wong, Y. J., Tran, S., Huang, C. F., Hsu, Y. C., Preda, C., Toyoda, H., ... & Nguyen, M. H. (2023). Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatology International, 1-12.